Posted by Michael Wonder on 19 Jun 2023
How health technology reassessment can support disinvestment in China’s national drug reimbursement list
15 June 2023 - A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment.
Pharmaceutical expenditure has been an important focus in China for the past three decades, particularly because of its role in the rising cost of healthcare and access to essential medicines.
